Ivabradine for the treatment of chronic stable angina and chronic heart failure

Published on 05 Feb 2018
Last Updated on 05 Feb 2018

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Ivabradine 5mg and 7.5mg tablets for the treatment of chronic heart failure in patients:

  • with New York Heart Association (NYHA) class II to IV stable chronic heart failure with systolic dysfunction (LVEF of 35% or less);

  • who are in sinus rhythm with a heart rate of 75 bpm or more and

  • who are given concomitant standard medical management with maximum tolerated doses of beta blockers, angiotensin-converting enzyme inhibitors and aldosterone antagonists, unless contraindicated.

Subsidy status

Ivabradine 5mg and 7.5mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

MAF assistance does not apply to the use of ivabradine for chronic stable angina.

Ivabradine for the treatment of CSA and CHF (5 Feb 2018) [PDF, 487 KB]